利奈唑胺治疗耐多药结核的神经系统不良事件:法国队列研究
该研究评估了2011-2016年法国57例接受利奈唑胺治疗的耐多药结核患者,发现58%出现神经或眼科体征,32%确诊周围神经病且78%不可逆,视神经病部分可逆,利奈唑胺谷浓度>2 mg/L者不良事件常见但无显著关联。
要点
- 利奈唑胺治疗耐多药结核患者中神经毒性常见且常不可逆。
- 需密切监测神经和眼科体征,并讨论最佳治疗时长。
- 谷浓度>2 mg/L与神经毒性无显著关联。
核心结论
- 利奈唑胺治疗耐多药结核时神经和眼科不良事件发生率高,周围神经病多不可逆。
研究设计与样本
- 回顾性队列研究,纳入2011-2016年法国57例接受>1剂利奈唑胺的耐多药结核患者。
主要发现
- 33例(58%)出现神经或眼科体征,18例(32%)确诊周围神经病。
- 78%的周围神经病在结核治疗结束后12个月时仍不可逆。
- 19例接受眼科评估者中14例有视神经病,其中2例完全逆转。
- 49例中16例(33%)利奈唑胺谷浓度>2 mg/L,其中14例(88%)发生不良事件。
- 谷浓度与神经毒性无显著关联。
关键数值与推荐
- 利奈唑胺剂量为600 mg/天,中位治疗时长13个月。
临床怎么用
- 对接受利奈唑胺治疗的耐多药结核患者应密切监测神经和眼科体征。
- 需讨论利奈唑胺的最佳治疗时长以平衡疗效与毒性。
局限性
- 样本量较小(57例),眼科评估仅19例。
- 回顾性设计,谷浓度与毒性关联可能受混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011-2016. Overall, patients received 600 mg/day of linezolid for a median of 13 months. In 33 (58%) patients, neurologic or ophthalmologic signs developed, and 18 (32%) had confirmed peripheral neuropathy, which for 78% was irreversible at 12 months after the end of TB treatment despite linezolid withdrawal. Among the 19 patients who underwent ophthalmologic evaluation, 14 patients had optic neuropathy that fully reversed for 2. A total of 16 (33%) of 49 patients had a linezolid trough concentration >2 mg/L, and among these, 14 (88%) experienced adverse effects. No significant association was found between trough concentration and neurologic toxicity. These findings suggest the need to closely monitor patients for neurologic signs and discuss optimal duration of linezolid treatment.
引用
- Jaspard M, Butel N, El Helali N, et al. Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France. Emerg Infect Dis. 2020. PMID: 32687026. doi:10.3201/eid2608.191499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。